| 6.83 0.13 (1.94%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.98 |
1-year : | 9.33 |
| Resists | First : | 6.84 |
Second : | 7.98 |
| Pivot price | 6.27 |
|||
| Supports | First : | 6.33 |
Second : | 6.03 |
| MAs | MA(5) : | 6.53 |
MA(20) : | 6.25 |
| MA(100) : | 5.93 |
MA(250) : | 5.05 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.3 |
D(3) : | 82.2 |
| RSI | RSI(14): 78 |
|||
| 52-week | High : | 6.84 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KZR ] has closed Bollinger Bands are 24% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.84 - 6.86 | 6.86 - 6.89 |
| Low: | 6.6 - 6.62 | 6.62 - 6.65 |
| Close: | 6.79 - 6.82 | 6.82 - 6.87 |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Fri, 09 Jan 2026
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
Mon, 05 Jan 2026
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know - Nasdaq
Wed, 12 Nov 2025
Kezar Life Sciences, Inc. SEC 10-Q Report - TradingView
Mon, 10 Nov 2025
Kezar Life Sciences to lay off 70% of workforce as dispute with FDA apparently continues - The Business Journals
Fri, 17 Oct 2025
KZR: William Blair Downgrades Kezar Life Sciences Rating | KZR S - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 59.1 (%) |
| Shares Short | 174 (K) |
| Shares Short P.Month | 251 (K) |
| EPS | -8.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.3 % |
| Return on Equity (ttm) | -56.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -6.11 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.81 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|